Literature DB >> 22199241

Differential gene expression in eyecup and retina of a mouse model of Stargardt-like macular dystrophy (STGD3).

Sharee Kuny1, Frédéric Gaillard, Yves Sauvé.   

Abstract

PURPOSE: To investigate differentially expressed genes in eyecup and retina of the ELOVL4 transgenic mouse, a model of Stargardt-like macular dystrophy (STGD3).
METHODS: We examined gene and protein expression in known pathways relevant to retinal degeneration using PCR arrays, Western blotting, and immunohistochemistry. Investigations were performed on ELOVL4 transgenic mice at 9 months, when 50% of rod (but no cone) photoreceptors had degenerated. Age-matched wild-type littermates served as controls.
RESULTS: Significant expression level changes were found in only 17 of the 252 genes examined. Nine were upregulated (Fgf2, Fgfr1, Ntf5, Cbln1, Ngfr, Ntrk1, Trp53, Tlr6, and Herpud1), and eight were downregulated (Ccl22, Ccr3, Il18rap, Nf1, Ccl11, Atf6β, Rpn1, and Serp1). Overexpression of FGF2 was detected at 1 month, before rod loss onset, and was maintained at high levels until cone loss (18 months). By 9 months, FGF2 overexpression was seen in photoreceptor cell bodies. Increased glial fibrillary acidic protein (GFAP) expression due to glial cell reactivity followed the same time course. Levels of NGFR/p75NTR remained invariant. Although present in rod outer segments at 1 month, the macrophage chemoattracting chemokine CCL22 became undetectable by 9 months, a likely consequence of progressive rod outer segment truncation.
CONCLUSIONS: At a mid-degeneration stage, major changes in gene expression in the ELOVL4 transgenic mouse retina included upregulation of Fgf2 and Fgfr1 and downregulation of Ccl22. Modulation of FGF2 occurred very early, concomitant with an increase in GFAP expression. Future studies will address which factors upstream of Fgf2 could provide potential therapeutic targets to slow photoreceptor degeneration in STGD3.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22199241     DOI: 10.1167/iovs.11-8418

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Treatment of Stargardt disease with dobesilate.

Authors:  Pedro Cuevas; Luis A Outeiriño; Javier Angulo; Guillermo Giménez-Gallego
Journal:  BMJ Case Rep       Date:  2012-10-12

2.  Mouse Models of Stargardt 3 Dominant Macular Degeneration.

Authors:  Peter Barabas; Aruna Gorusupudi; Paul S Bernstein; David Krizaj
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

3.  Modulation of inflammatory gene expression by the ribotoxin deoxynivalenol involves coordinate regulation of the transcriptome and translatome.

Authors:  Kaiyu He; Xiao Pan; Hui-Ren Zhou; James J Pestka
Journal:  Toxicol Sci       Date:  2012-09-11       Impact factor: 4.849

4.  Nicotinic receptor activation contrasts pathophysiological bursting and neurodegeneration evoked by glutamate uptake block on rat hypoglossal motoneurons.

Authors:  Silvia Corsini; Maria Tortora; Andrea Nistri
Journal:  J Physiol       Date:  2016-08-03       Impact factor: 5.182

5.  Photoreceptor-induced RPE phagolysosomal maturation defects in Stargardt-like Maculopathy (STGD3).

Authors:  Camille Dejos; Sharee Kuny; Woo Hyun Han; Heather Capel; Hélène Lemieux; Yves Sauvé
Journal:  Sci Rep       Date:  2018-04-13       Impact factor: 4.379

6.  Prenatal hypoxia is associated with long-term retinal dysfunction in rats.

Authors:  Stephane L Bourque; Sharee Kuny; Laura M Reyes; Sandra T Davidge; Yves Sauvé
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

7.  Effect of Anti-C5a Therapy in a Murine Model of Early/Intermediate Dry Age-Related Macular Degeneration.

Authors:  Christopher B Toomey; Michael Landowski; Mikael Klingeborn; Una Kelly; John Deans; Holly Dong; Ons Harrabi; Thomas Van Blarcom; Yik Andy Yeung; Ruslan Grishanin; John C Lin; Daniel R Saban; Catherine Bowes Rickman
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-02-01       Impact factor: 4.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.